[HTML][HTML] CD28 null CD4 T-cell expansions in autoimmune disease suggest a link with cytomegalovirus infection

A Bano, A Pera, A Almoukayed, THS Clarke… - …, 2019 - ncbi.nlm.nih.gov
Immunosenescence is thought to contribute to the increase of autoimmune diseases in older
people. Immunosenescence is often associated with the presence of an expanded …

[HTML][HTML] Lymphocytes change their phenotype and function in systemic lupus erythematosus and lupus nephritis

E Moysidou, M Christodoulou, G Lioulios… - International Journal of …, 2024 - mdpi.com
Systemic lupus erythematosus (SLE) is a complex autoimmune disease, characterized by
considerable changes in peripheral lymphocyte structure and function, that plays a critical …

Cytotoxic CD161− CD8+ TEMRA cells contribute to the pathogenesis of systemic lupus erythematosus

H **ong, M Cui, N Kong, J **g, Y Xu, X Liu, F Yang… - …, 2023 - thelancet.com
Background Systemic lupus erythematosus (SLE) is a prototypical autoimmune disease
affecting multiple organs and tissues with high cellular heterogeneity. CD8+ T cell activity is …

Exhausted but not senescent t lymphocytes predominate in lupus nephritis patients

G Lioulios, Z Mitsoglou, A Fylaktou, A Xochelli… - International Journal of …, 2022 - mdpi.com
Lupus nephritis (LN), a chronic inflammatory disease, is characterized by the substantial
disruption of immune homeostasis. This study examines its effects on the T lymphocyte …

MAIT cells altered phenotype and cytotoxicity in lupus patients are linked to renal disease severity and outcome

E Litvinova, C Bounaix, G Hanouna, J Da Silva… - Frontiers in …, 2023 - frontiersin.org
Introduction Systemic lupus erythematosus (SLE) is an autoimmune disease in which
circulating immune complexes can cause different types of glomerulonephritis, according to …

Histone‐Specific CD4+ T Cell Plasticity in Active and Quiescent Systemic Lupus Erythematosus

GA Ramirez, E Tassi, M Noviello… - Arthritis & …, 2024 - Wiley Online Library
Objective The aim of this study was to assess whether circulating histone‐specific T cells
represent tools for precision medicine in systemic lupus erythematosus (SLE). Methods …

Acazicolcept (ALPN-101), a dual ICOS/CD28 antagonist, demonstrates efficacy in systemic sclerosis preclinical mouse models

C Orvain, A Cauvet, A Prudent, C Guignabert… - Arthritis Research & …, 2022 - Springer
Background Uncontrolled immune response with T cell activation has a key role in the
pathogenesis of systemic sclerosis (SSc), a disorder that is characterized by generalized …

Association between changes in BLyS levels and the composition of B and T cell compartments in patients with refractory systemic lupus erythematosus treated with …

F Regola, S Piantoni, T Lowin, S Archetti… - Frontiers in …, 2019 - frontiersin.org
Introduction: Belimumab is a monoclonal antibody against soluble BLyS used for treatment
of refractory Systemic Lupus Erythematosus (SLE). Although B cells are the main target of …

First‐in‐human study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALPN‐101, a dual CD28/ICOS antagonist, in healthy adult subjects

J Yang, JD Lickliter, JL Hillson… - Clinical and …, 2021 - Wiley Online Library
Abstract ALPN‐101 (ICOSL vIgD‐Fc) is an Fc fusion protein of a human inducible T cell
costimulatory ligand (ICOSL) variant immunoglobulin domain (vIgD) designed to inhibit the …

Altered cell surface N-glycosylation of resting and activated T cells in systemic lupus erythematosus

E Szabó, Á Hornung, É Monostori, M Bocskai… - International Journal of …, 2019 - mdpi.com
Altered cell surface glycosylation in congenital and acquired diseases has been shown to
affect cell differentiation and cellular responses to external signals. Hence, it may have an …